File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: A meta-analysis

TitleThe efficacy of thymosin in the treatment of chronic hepatitis B virus infection: A meta-analysis
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2001
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2001, v. 15 n. 12, p. 1899-1905 How to Cite?
AbstractBackground: Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent. Aim: To conduct a meta-analysis to evaluate the efficacy of thymosin treatment in chronic hepatitis B virus infection. Methods: Randomized controlled trials comparing thymosin for over 24 weeks vs. placebo (or usual care) in the treatment of chronic hepatitis B virus infection were identified through MEDLINE, EMBASE and the Cochrane Register of Clinical Trials. Biochemical (normalization of transaminases) and virological (loss of hepatitis B virus DNA and hepatitis B e antigen) responses were analysed using the intention-to-treat method. The odds ratio was used to measure the magnitude of the efficacy. Results: Five trials (353 patients) were identified. The odds ratio (95% confidence interval) of the virological response of thymosin over placebo at the end of treatment, 6 months post-treatment and 12 months post-treatment were 0.56 (0.2-1.52), 1.67 (0.83-3.37) and 2.67 (1.25-5.68), respectively. There was an increasing trend of the virological response with time since the cessation of thymosin treatment (P = 0.02). There was no difference in the biochemical response between the thymosin and placebo groups at the end of treatment, 6 months post-treatment and 12 months post-treatment. Conclusions: Thymosin is effective in suppressing viral replication in chronic hepatitis B virus infection, but the effect is delayed until 12 months after the cessation of treatment.
Persistent Identifierhttp://hdl.handle.net/10722/92575
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, HLYen_HK
dc.contributor.authorTang, JLen_HK
dc.contributor.authorTam, Wen_HK
dc.contributor.authorSung, JJYen_HK
dc.date.accessioned2010-09-17T10:50:33Z-
dc.date.available2010-09-17T10:50:33Z-
dc.date.issued2001en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2001, v. 15 n. 12, p. 1899-1905en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/92575-
dc.description.abstractBackground: Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent. Aim: To conduct a meta-analysis to evaluate the efficacy of thymosin treatment in chronic hepatitis B virus infection. Methods: Randomized controlled trials comparing thymosin for over 24 weeks vs. placebo (or usual care) in the treatment of chronic hepatitis B virus infection were identified through MEDLINE, EMBASE and the Cochrane Register of Clinical Trials. Biochemical (normalization of transaminases) and virological (loss of hepatitis B virus DNA and hepatitis B e antigen) responses were analysed using the intention-to-treat method. The odds ratio was used to measure the magnitude of the efficacy. Results: Five trials (353 patients) were identified. The odds ratio (95% confidence interval) of the virological response of thymosin over placebo at the end of treatment, 6 months post-treatment and 12 months post-treatment were 0.56 (0.2-1.52), 1.67 (0.83-3.37) and 2.67 (1.25-5.68), respectively. There was an increasing trend of the virological response with time since the cessation of thymosin treatment (P = 0.02). There was no difference in the biochemical response between the thymosin and placebo groups at the end of treatment, 6 months post-treatment and 12 months post-treatment. Conclusions: Thymosin is effective in suppressing viral replication in chronic hepatitis B virus infection, but the effect is delayed until 12 months after the cessation of treatment.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.titleThe efficacy of thymosin in the treatment of chronic hepatitis B virus infection: A meta-analysisen_HK
dc.typeArticleen_HK
dc.identifier.emailTam, W: wwstam@hkucc.hku.hken_HK
dc.identifier.authorityTam, W=rp01378en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1365-2036.2001.01135.xen_HK
dc.identifier.pmid11736720-
dc.identifier.scopuseid_2-s2.0-0035663014en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035663014&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1899en_HK
dc.identifier.epage1905en_HK
dc.identifier.isiWOS:000172788300008-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChan, HLY=16038785900en_HK
dc.identifier.scopusauthoridTang, JL=12771935200en_HK
dc.identifier.scopusauthoridTam, W=9740867000en_HK
dc.identifier.scopusauthoridSung, JJY=35405352400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats